Working with TipRanks
Follow Us
Research Tools
Calendars
Calculators
Education
About Us
Working with TipRanks
Follow Us
Mirum Pharmaceuticals Inc (MIRM)
NASDAQ:MIRM
RESEARCH TOOLSreports
Mirum Pharmaceuticals (MIRM) Stock Price & Analysis
489 Followers
MIRM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$17.32 - $33.39
Previous Close$30.72
Volume296.14K
Average Volume (3M)593.87K
Market Cap
$1.18B
Enterprise ValueN/A
Total Cash (Recent Filing)$329.95M
Total Debt (Recent Filing)$307.83M
Price to Earnings (P/E)-6.5
Beta0.51
Next Earnings
Nov 08, 2023EPS Estimate
-$1.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.76
Shares Outstanding38,297,975
10 Day Avg. Volume1,032,204
30 Day Avg. Volume593,870
Standard Deviation0.38
R-Squared0.03
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)55.15
Price to Sales (P/S)36.20
Price to Cash Flow (P/CF)-131.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$57.20Price Target Upside86.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Mirum Pharmaceuticals News
Stock Analysis & Ideas‘Load Up,’ Says Raymond James About These 2 ‘Strong Buy’ Stocks
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Product Insights
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MIRM FAQ
What was Mirum Pharmaceuticals Inc’s price range in the past 12 months?
Mirum Pharmaceuticals Inc lowest stock price was $17.32 and its highest was $33.39 in the past 12 months.
What is Mirum Pharmaceuticals Inc’s market cap?
Currently, no data Available
When is Mirum Pharmaceuticals Inc’s upcoming earnings report date?
Mirum Pharmaceuticals Inc’s upcoming earnings report date is Nov 08, 2023 which is in 46 days.
How were Mirum Pharmaceuticals Inc’s earnings last quarter?
Mirum Pharmaceuticals Inc released its earnings results on Aug 03, 2023. The company reported -$1.94 earnings per share for the quarter, missing the consensus estimate of -$0.755 by -$1.185.
Is Mirum Pharmaceuticals Inc overvalued?
According to Wall Street analysts Mirum Pharmaceuticals Inc’s price is currently Undervalued.
Does Mirum Pharmaceuticals Inc pay dividends?
Mirum Pharmaceuticals Inc does not currently pay dividends.
What is Mirum Pharmaceuticals Inc’s EPS estimate?
Mirum Pharmaceuticals Inc’s EPS estimate is -$1.43.
How many shares outstanding does Mirum Pharmaceuticals Inc have?
Mirum Pharmaceuticals Inc has 38,297,974 shares outstanding.
What happened to Mirum Pharmaceuticals Inc’s price movement after its last earnings report?
Mirum Pharmaceuticals Inc reported an EPS of -$1.94 in its last earnings report, missing expectations of -$0.755. Following the earnings report the stock price went up 6.31%.
Which hedge fund is a major shareholder of Mirum Pharmaceuticals Inc?
Among the largest hedge funds holding Mirum Pharmaceuticals Inc’s share is Perceptive Advisors LLC. It holds Mirum Pharmaceuticals Inc’s shares valued at 16M.
---
Mirum Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$57.20 (86.20% Upside)
$57.20 (86.20% Upside)
Blogger Sentiment
Bullish
MIRM Sentiment 100%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 2.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $4.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.5%
Last 30 Days ▼ 1.5%
Last 30 Days ▼ 1.5%
News Sentiment
Neutral
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
36.23%
12-Months-Change
Fundamentals
Return on Equity
-186.27%
Trailing 12-Months
Asset Growth
49.24%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Mirum Pharmaceuticals Inc
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its product candidates include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz on May 7, 2018 and is headquartered in Foster City, CA.
---
Top 5 ETFs holding MIRM
Vanguard Total Stock Market ETF
$27.43M
Xtrackers MSCI USA SWAP UCITS ETF Capitalisation 1C
$971.80K
Schwab U.S. Broad Market ETF
$548.77K
iShares Russell 3000 ETF
$182.57K
Vanguard Russell 3000 ETF
$44.22K
Up to five ETFs with an Outperform Smart Score that hold MIRM. The ETFs are listed according to market value of MIRM within the ETF
Bioxcel Therapeutics
―
Liquidia Technologies
―
Xeris Pharmaceuticals
―
Kala Pharmaceuticals
―
---